ArticleEpilepsia2026
Olig2-specific loss-of-function Slc35a2 results in hypomyelination and spontaneous seizures.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neurocentric No More? Oligodendrocyte Dysfunction Supports Epileptogenesis.Epilepsy currents · 2026Article
- Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE): genetics, mechanisms and precision therapy.Acta neuropathologica · 2026Review
- Disrupted O-GalNAc glycosylation as a mechanism and biomarker ofbioRxiv : the preprint server for biology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveMalformations of cortical development represent major causes of drug-resistant epilepsy, with mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy recognized as a distinct pathological entity. Pathogenic X-linked SLC35A2, encoding the uridine diphosphate-galactose transporter, has been implicated in this condition. In this study, we investigated the behavioral, electrophysiological, and cellular/molecular phenotypes associated with loss-of-function Slc35A2 mutations in oligodendrocytes.
methodsA conditional knockout (cKO) mouse model was generated using an Olig2-specific promoter. Behavioral assessments included neurological scoring, open field, locomotor habituation, and pentylenetetrazole-induced seizure testing in 95 mice (31 female controls, 22 female cKO, 26 male controls, 16 male cKO), aged 4-18 weeks. Continuous electroencephalographic (EEG) studies were performed in eight control and eight cKO mice implanted with cortical electrodes. Histopathological analyses and immunohistochemistry were performed at postnatal days 15, 21, and 60.
resultsLoss-of-function Slc35a2 mice exhibited significantly reduced body weight, progressive motor dysfunction, and reduced survival compared to controls. Males demonstrated more severe motor dysfunction compared to females due to the X-linked nature of Slc35a2. Video-EEG monitoring captured spontaneous electroclinical seizures in cKO mice, accompanied by frequent interictal spiking, despite preserved neuronal integrity. Histological and immunohistochemical evaluation revealed extensive subcortical hypomyelination, reactive gliosis, and significant reduction of Olig2-positive oligodendrocytes in the corpus callosum. SIGNIFICANCE: Our results demonstrate that loss of SLC35A2 function in oligodendrocytes is sufficient to reproduce pathological and clinical features observed in human mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy. Spontaneous seizures in the absence of direct neuronal genetic abnormalities highlight a central role for oligodendrocyte dysfunction and hypomyelination in epileptogenesis. These findings challenge the neuron-centric view of epilepsy and suggest that targeting glial dysfunction may offer novel therapeutic opportunities. Further studies are warranted to delineate cellular interactions driving epileptogenesis and to explore glia-centered treatment strategies for drug-resistant epilepsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.